Fever of unknown origin (FUO) in children presents a diagnostic challenge. The differential diagnosis includes systemic-onset juvenile idiopathic arthritis (JIA), an autoinflammatory syndrome associated with activation of phagocytic cells that, at presentation, is difficult to differentiate from severe systemic infections. The aim of this study was to investigate whether serum concentrations of the phagocytic proinflammatory protein S100A12 may help in deciding whether to treat patients with FUO with antibiotics or immunosuppressive agents.

Methods

Serum samples were obtained from 45 healthy control subjects and from 240 patients (60 with systemic-onset JIA, 17 with familial Mediterranean fever [FMF], 18 with neonatal-onset multisystem inflammatory disease [NOMID], 17 with Muckle-Wells syndrome [MWS], 40 with acute lymphoblastic leukemia [ALL], 5 with acute myeloblastic leukemia [AML], and 83 with systemic infections). All samples were collected at the time of presentation, before the initiation of any treatment, and concentrations of S100A12 were determined by enzyme-linked immunosorbent assay.

Results

The mean ± 95% confidence interval serum levels of S100A12 were as follows: in patients with JIA, 7,190 ± 2,690 ng/ml; in patients with FMF, 6,720 ± 4,960 ng/ml; in patients with NOMID, 720 ± 450 ng/ml; in patients with MWS, 150 ± 60 ng/ml; in patients with infections, 470 ± 160 ng/ml; in patients with ALL, 130 ± 80 ng/ml; in patients with AML, 45 ± 60 ng/ml; in healthy control subjects, 50 ± 10 ng/ml. The sensitivity and specificity of S100A12 to distinguish between systemic-onset JIA and infections were 66% and 94%, respectively.

Conclusion

S100A12, a marker of granulocyte activation, is highly overexpressed in patients with systemic-onset JIA or FMF, which may point to as-yet unknown common inflammatory mechanisms in these diseases. The measurement of S100A12 serum levels may provide a valuable diagnostic tool in the evaluation of FUO.

REFERENCES

1 Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40: 1–30.
10.1097/00005792-196102000-00001
CAS PubMed Web of Science® Google Scholar
2 Durack DT, Street AC. Fever of unknown origin: reexamined and redefined [review]. Curr Clin Top Infect Dis 1991; 11: 35–51.
CAS PubMed Google Scholar
3 Arnow PM, Flaherty JP. Fever of unknown origin [review]. Lancet 1997; 350: 575–80.
10.1016/S0140-6736(97)07061-X
CAS PubMed Web of Science® Google Scholar
4 Gaeta GB, Fusco FM, Nardiello S. Fever of unknown origin: a systematic review of the literature for 1995–2004 [review]. Nucl Med Commun 2006; 27: 205–11.
10.1097/00006231-200603000-00002
PubMed Web of Science® Google Scholar
5 Woo P, Wedderburn LR. Juvenile chronic arthritis [review]. Lancet 1998; 351: 969–73.
10.1016/S0140-6736(05)60640-X
CAS PubMed Web of Science® Google Scholar
6 Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis [review]. Baillieres Clin Rheumatol 1998; 12: 245–71.
10.1016/S0950-3579(98)80018-6
CAS PubMed Web of Science® Google Scholar
7 Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome [review]. Nat Clin Pract Rheumatol 2006; 2: 28–34.
10.1038/ncprheum0084
PubMed Web of Science® Google Scholar
8 Jarvis JN. Pathogenesis and mechanisms of inflammation in the childhood rheumatic diseases [review]. Curr Opin Rheumatol 1998; 10: 459–67.
10.1097/00002281-199809000-00011
CAS PubMed Google Scholar
9 Niki Y, Yamada H, Seki S, Kikuchi T, Takaishi H, Toyama Y, et al. Macrophage- and neutrophil-dominant arthritis in human IL-1α transgenic mice. J Clin Invest 2001; 107: 1127–35.
10.1172/JCI11530
CAS PubMed Web of Science® Google Scholar
10 Muller K, Herner EB, Stagg A, Bendtzen K, Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 1998; 37: 562–9.
10.1093/rheumatology/37.5.562
CAS PubMed Web of Science® Google Scholar
11 Foell D, Wittkowski H, Hammerschmidt I, Wulffraat NM, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 2004; 50: 1286–95.
10.1002/art.20125
CAS PubMed Web of Science® Google Scholar
12 Foell D, Wittkowski H, Roth J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis [review]. Nat Clin Pract Rheumatol 2007; 3: 382–90.
10.1038/ncprheum0531
CAS PubMed Web of Science® Google Scholar
13 Wittkowski H, Sturrock A, van Zoelen MA, Viemann D, van der Poll T, Hoidal JR, et al. Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit Care Med 2007; 35: 1369–75.
10.1097/01.CCM.0000262386.32287.29
PubMed Web of Science® Google Scholar
14 Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2007; 282: 4218–31.
10.1074/jbc.M608888200
CAS PubMed Web of Science® Google Scholar
15 Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889–901.
10.1016/S0092-8674(00)80801-6
CAS PubMed Web of Science® Google Scholar
16 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949–55.
10.1172/JCI200114002
CAS PubMed Web of Science® Google Scholar
17 Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease [review]. Arthritis Rheum 2004; 50: 3762–71.
10.1002/art.20631
CAS PubMed Web of Science® Google Scholar
18 Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390–2.
PubMed Web of Science® Google Scholar
19 Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al, for the Italian Pediatric Rheumatology Study Group. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 38–41.
10.1136/ard.57.1.38
CAS PubMed Web of Science® Google Scholar
20 Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9.
10.1002/art.1780400703
CAS PubMed Web of Science® Google Scholar
21 Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847–53.
10.1136/gut.52.6.847
CAS PubMed Web of Science® Google Scholar
22 Vogl T, Propper C, Hartmann M, Strey A, Strupat K, van den Bos C, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem 1999; 274: 25291–6.
10.1074/jbc.274.36.25291
CAS PubMed Web of Science® Google Scholar
23 Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, et al. Fecal S100A12 as non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007; 56: 1706–13.
10.1136/gut.2006.113431
CAS PubMed Web of Science® Google Scholar
24 Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N Engl J Med 2006; 355: 581–92.
10.1056/NEJMoa055137
CAS PubMed Web of Science® Google Scholar
25 American College of Rheumatology Ad Hoc Committee on Immunologic Testing. Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. Arthritis Rheum 2002; 47: 429–33.
10.1002/art.10381
PubMed Web of Science® Google Scholar
26 Federici L, Rittore-Domingo C, Kone-Paut I, Jorgensen C, Rodiere M, Le Quellec A, et al. A decision tree for genetic diagnosis of hereditary periodic fever in unselected patients. Ann Rheum Dis 2006; 65: 1427–32.
10.1136/ard.2006.054304
CAS PubMed Web of Science® Google Scholar
27 Drenth JP, van der Meer JW. Hereditary periodic fever [review]. N Engl J Med 2001; 345: 1748–57.
10.1056/NEJMra010200
CAS PubMed Web of Science® Google Scholar
28 Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479–86.
10.1084/jem.20050473
CAS PubMed Web of Science® Google Scholar
29 Fitzgerald AA, LeClercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum 2005; 52: 1794–803.
10.1002/art.21061
CAS PubMed Web of Science® Google Scholar
30 Dinarello CA. Blocking IL-1 in systemic inflammation [review]. J Exp Med 2005; 201: 1355–9.
10.1084/jem.20050640
CAS PubMed Web of Science® Google Scholar
31 Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008; 67: 302–8.
10.1136/ard.2007.076034
CAS PubMed Web of Science® Google Scholar
32 Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986–94.
10.1189/jlb.69.6.986
CAS PubMed Web of Science® Google Scholar
33 Foell D, Ichida F, Vogl T, Yu X, Chen R, Miyawaki T, et al. S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270–2.
10.1016/S0140-6736(03)12986-8
CAS PubMed Web of Science® Google Scholar
34 Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383–9.
10.1093/rheumatology/keg385
CAS PubMed Web of Science® Google Scholar
35 Foell D, Hernandez-Rodriguez J, Sanchez M, Vogl T, Cid MC, Roth J. Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J Pathol 2004; 204: 311–6.
10.1002/path.1660
CAS PubMed Web of Science® Google Scholar
36 Wittkowski H, Foell D, af Klint E, De Rycke L, De Keyser F, Frosch M, et al. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1020–5.
10.1136/ard.2006.061507
CAS PubMed Web of Science® Google Scholar
37 Sobieska M, Fassbender K, Aeschlimann A, Bourgeois P, Mackiewicz S, Muller W. Still's disease in children and adults: a distinct pattern of acute-phase proteins. Clin Rheumatol 1998; 17: 258–60.
10.1007/BF01451062
CAS PubMed Web of Science® Google Scholar
38 Ogilvie EM, Khan A, Hubank M, Kellam P, Woo P. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 1954–65.
10.1002/art.22644
CAS PubMed Web of Science® Google Scholar
39 Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007; 204: 2131–44.
10.1084/jem.20070070
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume58, Issue12

December 2008

Pages 3924-3931

S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin

Abstract

Objective

Methods

Results

Conclusion

REFERENCES

Citing Literature

References

Related

Information